<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
Financial Data Schedule
Mylan Laboratories Inc. and Subsidiaries
Article 5 of Regulation S-X
he schedule contains summary financial information extracted from the
Consolidated Balance Sheet at June 30, 2000, and the Consolidated Statement of
Earnings for the three months ended June 30, 2000, and is qualified in its
entirety by reference to such financial statements.
</LEGEND>
<CIK> 0000069499
<NAME> none
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> MAR-31-2001
<PERIOD-END> JUN-30-2000
<CASH> 181,304
<SECURITIES> 58,472
<RECEIVABLES> 244,378
<ALLOWANCES> 70,992
<INVENTORY> 208,326
<CURRENT-ASSETS> 707,664
<PP&E> 282,359
<DEPRECIATION> 109,838
<TOTAL-ASSETS> 1,364,818
<CURRENT-LIABILITIES> 283,464
<BONDS> 32,829
0
0
<COMMON> 65,217
<OTHER-SE> 965,910
<TOTAL-LIABILITY-AND-EQUITY> 1,364,818
<SALES> 167,255
<TOTAL-REVENUES> 167,255
<CGS> 92,279
<TOTAL-COSTS> 92,279
<OTHER-EXPENSES> 55,618
<LOSS-PROVISION> 305
<INTEREST-EXPENSE> 9
<INCOME-PRETAX> (118,889)
<INCOME-TAX> (42,800)
<INCOME-CONTINUING> (76,089)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (76,089)
<EPS-BASIC> (.59)
<EPS-DILUTED> (.59)
</TABLE>
